An observational study in Aorta Aneurysm, sponsored by University Paul Sabatier of Toulouse. Completed. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by University Paul Sabatier of Toulouse · Observational
Proximal type 1A endoleak is a worrying complication after endovascular repair of an abdominal aortic aneurysm (EVAR). The ideal solution is not obvious between relining by FEVAR and endograft explantation.
A retrospective french multicentric study was performed between 2010 and 2023 to compare the outcomes and the efficiency of both technics and propose a decision algorithm for the management of type 1A endoleak after EVAR.
Patient presenting a type 1A endoleak after EVAR for AAA during the follow up
Exclusion Criteria:
Device: FEVAR
Device: Explantation
Relining the EVAR with FEVAR
open surgery to explant the previous EVAR
Post operative mortality
Patient death after the treatment of type 1A endoleak
Time frame: day 30 post operative
Major adverse cardiovascular event (MACE) post operative
Patient presenting after surgery a composite score (MACE) including * nonfatal stroke, * nonfatal myocardial infarction * cardiovascular death
Time frame: day 30 post operative
Redo surgery after type 1A endoleak surgery
Reintervention after FEVAR or explantation surgery
Time frame: 30 day, 6 months, 12 months, 24 months
Efficiency of the treatment
No reintervention after open surgery or Thrombosis of the aneurysmal sac after FEVAR
Time frame: 30 day, 6 months, 12 months, 24 months
No study locations are listed for this record.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Paul Sabatier of Toulouse